Overview
We advise companies on compliance with U.S. Food and Drug Administration (FDA) regulations, guidance, policies, and procedures regarding drugs, medical devices, human and animal foods, dietary supplements, and cosmetics. Our compliance counseling experience spans a broad range of contexts including:
- Development of effective compliance programs for pharmaceutical manufacturers, including standard operating procedures (SOPs), employee codes of conduct, internal investigations, and self-reporting;
- Informed consent, institutional review board (IRB) approval, and clinical trial registration and reporting;
- Pharmaceutical and food advertising and promotion;
- Change reporting and supplemental application requirements for drugs;
- OTC monograph requirements for drug product formulation and labeling;
- Product safety monitoring and adverse event reporting;
- Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), and Good Laboratory Practices (GLP);
- Product formulation, labeling, and claims including permissible product ingredients, health claims, nutrient content, and “structure/function” claims for foods;
- Assist all actors in the medical device field with premarket issues, market entry strategies, and postmarket compliance. This includes marketing and promotional strategies, compliance reviews and liability exposure assessments, medical device reporting compliance, cGMP and quality system regulation (QSR) compliance, and medical device reporting (MDR).
- Food Safety Modernization Act compliance, involving hazard analysis, preventive control and corrective action plans, supplier verification programs, track-and-trace, and recordkeeping requirements; and
- Import and export requirements, international trade (customs and country-of-origin matters, European Union (EU) regulation and policies).
Contact Us
Ann M. Begley
202.719.4585 | abegley@wiley.law
David B. Weinberg
202.719.7102 | dweinberg@wiley.law
Ryan Michael Fournier
202.719.7389 | rfournier@wiley.law
View all practice area professionals >
Related Capabilities
- Drug Product Development and Approval Strategies
- Due Diligence and Transactional Support
- Enforcement & Recalls
- FDA Regulatory Compliance
- Hatch-Waxman Act Litigation
- Human and Animal Food Ingredient Review and Approval Strategies
- Labeling, Advertising, and Promotion
- Litigation and Administrative Advocacy
- Medical Devices
- White Collar Defense & Government Investigations
Related News & Insights
- Media MentionAnn Begley Discusses Delay in FDA’s OTC Monograph User Fee Program ScheduleHBW InsightJanuary 6, 2021Ann M. Begley
- Media MentionBob Hibbert Discusses FDA and USDA Regulatory Approval Process for Cell-Based MeatsFood DiveDecember 15, 2020Bob Hibbert
- Press Release28 Wiley Attorneys Recognized Across 17 Practice Areas in 2021 Edition of The Best Lawyers in America®August 20, 2020Rand L. Allen, Attison L. Barnes, III, Ralph J. Caccia, Christine E. Connelly, Scott D. Delacourt, Henry Gola, Amb. David A. Gross, Jennifer D. Hindin, Theodore A. Howard, Kathleen A. Kirby, Ari Meltzer, Bert W. Rein, Bennett L. Ross, Peter D. Shields, Daniel J. Standish, Lawrence M. Sung, Michael E. Toner, Joshua S. Turner, David B. Weinberg, Richard E. Wiley, Bruce L. McDonald, Lukman S. Azeez, Lindy C. Bathurst, Cynthia C. Galvez, Tatiana Sainati, Kathleen E. Scott, Margaret T. Karchmer, Gary S. Ward
- Media MentionBert Rein Discusses Whether HHS’s Proposal for Mandatory Price Disclosure Infringes on Free SpeechBioCenturyOctober 24, 2018Bert W. Rein